SCHEMBL2215529

SCHEMBL2215529

CC(C)(N)c1ccc(C(=O)Nc2ccc(Nc3nc(-c4cccc5c4oc4ccccc45)cc4ccnn34)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
HSD17B10 Q99714 3/20 0.38
KDM4E B2RXH2 3/20 0.38
HPGD P15428 2/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TRPV1 Q8NER1 3/20 0.35
MAPT P10636 7/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
TP53 P04637 3/20 0.34
KDR P35968 1/20 0.34
TEK Q02763 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
POLB P06746 1/20 0.33
BTK Q06187 1/20 0.33
P2RX3 P56373 1/20 0.33
MYC P01106 1/20 0.33
DNMT1 P26358 1/20 0.33
MAP2K3 P46734 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215249 0.95 SMN1; SMN2 (0.37) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL2213218 0.94 TRPV1 (0.42) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL2214233 0.91 DNMT1 (0.42) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL2216183 0.90 ALDH1A1 (0.42) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL2214178 0.89 KDM4E (0.39) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL2215221 0.89 MAPT (0.42) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL2215080 0.89 LMNA (0.50) ALDH1A1HSD17B10KDM4EHPGDLMNA
Hydrochloric Acid SCHEMBL2215243 0.88 HSD17B10 (0.38) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL2214311 0.88 KCNK9 (0.44) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL2212315 0.88 MAPT (0.41) ALDH1A1HSD17B10KDM4EHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 ALDH1A1 1334/4885HSD17B10 2843/4885KDM4E 3784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.